Japan Pharm Companies Focus On Microdosing Compounds
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers are turning increasingly to microdosing of compounds in humans to test how the drugs are absorbed and metabolized before subjecting them to clinical trials. Japan's Health Ministry established guidelines for the practice last year, following similar efforts in the United States and Europe. Eisai began conducting microdosing tests in Europe last year and now is doing joint research with 13 other firms, including Daiichi Sankyo, Mitsubisihi Tanabe Pharma and Ono Pharmaceutical, all working with research organizations. The head of Eisai's research and development section said the results have been "enormously useful." (Click here for more - a subscription may be required